We found that increasing or decreasing our estimates of tumor sizes at clinical presentation in BRCA1 mutation carriers or in normal-risk women over a 2-fold range had a negligible effect on our conclusions (Table 3; Figures S7A, S7B, S8A, and S8B). Here, BRCA1 is linked to neoplasm.